UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/665,460	09/19/2003	Georges Freyssinet	A335992-PCT-USA-A(072667.	6831
21003 7590 11/01/2007 BAKER BOTTS L.L.P.		EXAMINER NIEBAUER, RONALD T		
30 ROCKEFELLER PLAZA				
44TH FLOOR NEW YORK, NY 10112-4498			ART UNIT	PAPER NUMBER
NEW TORK, N	NI JUII2 <del>-44</del> 96	•	1654	
			[	
			NOTIFICATION DATE	DELIVERY MODE
			11/01/2007	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

DLNYDOCKET@BAKERBOTTS.COM



### UNITED STATES DEPARTMENT OF COMMERCE

#### U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO./ FILING DATE FIRST NAMED INVENTOR / ATTORNEY DOCKET NO. PATENT IN REEXAMINATION

10665460 A(072667. 9/19/2003

FREYSSINET ET AL.

A335992-PCT-USA-

BAKER BOTTS L.L.P. 30 ROCKEFELLER PLAZA 44TH FLOOR NEW YORK, NY 10112-4498 EXAMINER

Ronald T. Niebauer

ART UNIT PAPER

1654

20071016

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 (see attached notice to comply). Specifically, the peptide DRNDTRNLSV (page 21 of specification) does not appear to have a corresponding sequence from among the 160 submitted sequences. Numerous other sequences appear for example on pages 22.28.29.34.36-39.43.45.49-56 without sequence identifiers (See 1.821 (d)) and possibly without a corresponding sequence in computer readable form or a papter copy. All sequences should have a sequence identifier and a corresponding sequence listing via computer readable form and paper copy. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.APPLICANT IS GIVEN 1 MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response. The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following: 1. Electronically submitted through EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual - ePAVE) 2. Mailed to:Mail Stop SequenceCommissioner for PatentsP.O. Box 22313 1450Alexandria, VA 22313 14503. Hand Carry, Federal Express, United Parcel Service or other delivery service to: U.S. Patent and Trademark OfficeMail Stop SequenceCustomer WindowRandolph Building401 Dulaney StreetAlexandria, VA 22314. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ronald T. Niebauer whose telephone number is 571-270-3059. The examiner can normally be reached on Monday-Thursday, 7:30am-5:00pm, alt. Friday, EST.If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

> ANISH GUPTA PRIMARY EXAMINER

Ph

# Notice to Comply Application No. 10/665,460 Freyssinet et al. Examiner Art Unit Ronald T. Niebauer 1654

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
_	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: The peptide DRNDTRNLSV (page 21 of specification) does not appear to have a corresponding sequence from any the 160 submitted sequences. Numerous other sequences appear for example on pages 22,28,29,34,36-39,43,45,49-56 nout sequence identifiers (See 1.821 (d)) and possibly without a corresponding sequence in computer readable form or a papter y.
	plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the cification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, ude no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
	For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRF Submission Help, call (571) 272-2510

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

PatentIn Software is Available At www.USPTO.gov

Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845

PatentIn Software Program Support